Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Posts tagged ‘U.S. Food and Drug Administration’

Alimta gets a new approval in first-line non-small cell lung cancer with specific histologies

This week, Lilly received approval from the U.S. Food and Drug Administration (FDA) for the use of Alimta (pemetrexed), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with non squamous histology. Alimta is not indicated for treatment of patients with squamous cell non-small cell lung cancer.

According to the American Cancer Society, lung cancer (small cell and non-small cell) is the second most common cancer in both men (after prostate cancer) and women (after breast cancer).  It accounts for about 15% of all new cancers. During 2008, there will be about 215,020 new cases of lung cancer (114,690 among men and 100,330 among women).

2 Comments

FTC warns about bogus cancer cures

The absolute last thing you need when you or a family member is seriously ill with cancer is an illegal scam from snake oil salesmen.

The Federal Trade Commission (FTC)
has charged five companies with making false and misleading claims for
cancer cures and said yesterday that it has reached settlements with several others.  In their press release, the five companies being sued for false and
deceptive advertising will go before administrative law judges and included the following:

Omega Supply

Native Essence Herb Company

Daniel Chapter One

Gemtronics

Herbs For Cancer